EYENOVIA INC. - COMMON STOCK

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 8 2024 17:11:42 提供 Nasdaq GlobeNewswire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

23 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5M Registered Direct Offering

28 6 2024 08:00:14 提供 Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

15 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

14 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25 4 2024 07:00:01 提供 Nasdaq GlobeNewswire

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

08 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

03 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

18 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

13 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

11 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

05 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

13 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

16 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

13 11 2023 16:05:01 提供 Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

06 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

02 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

30 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

09 10 2023 07:00:00 提供 Nasdaq GlobeNewswire